Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24136313 | 0.86 | TSHR (0.37) | TSHR | |
| SCHEMBL25868489 | 0.82 | — | — | |
| SCHEMBL19541808 | 0.81 | ALDH1A1 (0.34) | TSHRALDH1A1PHF8KDM2A | |
| SCHEMBL14190510 | 0.81 | HRH3 (0.40) | PLA2G2CTSHRPLA2G4BALDH1A1 | |
| SCHEMBL16329244 | 0.80 | MEN1 (0.34) | — | |
| SCHEMBL23802550 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL20032308 | 0.79 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL14474311 | 0.78 | PHF8 (0.31) | PHF8KDM2A | |
| SCHEMBL21286081 | 0.78 | ALDH1A1 (0.39) | TSHRALDH1A1PHF8KDM2A | |
| SCHEMBL19379975 | 0.78 | PHF8 (0.32) | PHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | PLA2G2C 635/4885TSHR 4137/4885PLA2G4B 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.